Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on May 20, 2026 reporting Item 8.01 (Other Events). Positive Phase 3 SELVA and Phase 2 TOIVA clinical data presented at the ISSVA World Congress 2026.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Positive Phase 3 SELVA and Phase 2 TOIVA clinical data presented at the ISSVA World Congress 2026
- Findings potentially support Palvella’s clinical development programs and investor view of pipeline value
- Press release filed as Exhibit 99.1 for detailed efficacy and safety results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.